Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding
Authors
Keywords
-
Journal
HEMATOLOGICAL ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2018-03-07
DOI
10.1002/hon.2503
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies
- (2017) J. J. Shatzel et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib
- (2017) Khai Li Chai et al. LEUKEMIA & LYMPHOMA
- Effect of CYP2D6 polymorphisms on the pharmacokinetics of propafenone and its two main metabolites
- (2017) Mohammad-Reza Rouini et al. THERAPIE
- Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function
- (2016) Rachel A. Rigg et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study
- (2016) Philip A. Thompson et al. BRITISH JOURNAL OF HAEMATOLOGY
- 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
- (2016) Paulus Kirchhof et al. EUROPEAN HEART JOURNAL
- Drug-drug interactions of non-vitamin K oral anticoagulants
- (2016) Christos Voukalis et al. Expert Opinion on Drug Metabolism & Toxicology
- Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group
- (2016) M. Winqvist et al. HAEMATOLOGICA
- Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients
- (2016) HAEMATOLOGICA
- Adverse event potentially due to an interaction between ibrutinib and verapamil: a case report
- (2016) E. Lambert Kuhn et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- The changing circumstance of atrial fibrillation - progress towards precision medicine
- (2016) A. J. Camm et al. JOURNAL OF INTERNAL MEDICINE
- Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study
- (2016) Martin Dreyling et al. LANCET
- Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study
- (2016) Asher Chanan-Khan et al. LANCET ONCOLOGY
- Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)
- (2016) Tait D. Shanafelt et al. LEUKEMIA & LYMPHOMA
- Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group
- (2016) M. Winqvist et al. HAEMATOLOGICA
- Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients
- (2016) HAEMATOLOGICA
- Ibrutinib Inhibits Platelet Integrin αIIbβ3Outside-In Signaling and Thrombus Stability But Not Adhesion to CollagenSignificance
- (2015) Alexander P. Bye et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Response: Additional data needed for a better understanding of the potential relationship between atrial fibrillation and ibrutinib
- (2015) J. C. Byrd et al. BLOOD
- Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib
- (2015) J. C. Byrd et al. BLOOD
- Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
- (2015) M. L. Wang et al. BLOOD
- Serum flecainide S/R ratio reflects the CYP2D6 genotype and changes in CYP2D6 activity
- (2015) Kosuke Doki et al. Drug Metabolism and Pharmacokinetics
- Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation
- (2015) Hein Heidbuchel et al. EUROPACE
- The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia
- (2015) A. Wiestner HAEMATOLOGICA
- Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib
- (2015) A. H. Lipsky et al. HAEMATOLOGICA
- Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban
- (2015) C. Stöllberger et al. HERZ
- Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
- (2015) Steven P. Treon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
- (2015) Jan A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia
- (2015) A. Wiestner HAEMATOLOGICA
- Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib
- (2015) A. H. Lipsky et al. HAEMATOLOGICA
- Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling
- (2014) J. R. McMullen et al. BLOOD
- Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study
- (2014) Jan A Burger et al. LANCET ONCOLOGY
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
- (2014) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
- (2013) Christian T Ruff et al. LANCET
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- (2013) Michael L. Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation
- (2010) Ron Pisters et al. CHEST
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More